Close Menu

financial results

The company is delaying the publication of its business and financial update for the first half of 2019 to allow for an ongoing review by its auditors.

The company said it is pushing to begin simultaneous clinical trials for multiple small panel-based tests for its sample-to-answer Savanna platform.

The appointment of a former Roche executive as the firm's new COO is viewed as a significant event for a firm still in the early stages of driving adoption of its Pheno system.

The firm experienced a 30 percent jump in sales of immunoassays, attributed in part to a $6.2 million increase in influenza revenues year-over-year.

NantHealth's net loss fell by 37 percent, to $14.7 million, as revenue from software-related revenue jumped by 23 percent while expenses fell.

The company reported sales of 3,129 OVA1 tests in the quarter, up 66 percent from 1,884 tests in the year-ago quarter.

The Gaithersburg, Maryland-based company continues to await US Food and Drug Administration clearance for its antimicrobial resistance test.

Revenues were $226.4 million, down from $263.7 million for the same quarter last year, but above the Wall Street estimate of $225.6 million.

The company beat analyst estimates on the top and bottom line, driven by sales of its Panorama noninvasive prenatal and Horizon carrier screening tests.

In an earnings call, the firm said it sees growth continuing for the BD Max, BD Cor, and Phoenix systems, and in China in general.

Pages